MPN Clinical Trial update with Dr. Abu-Zeinah, from ASH 2021 by David Wallace TRANSCRIPT | MPN Clinical Trials, 2022 Update David Wallace: Hello, I’m David Wallace, founder of PV Reporter and our nonprofit organization MPN Cancer Connection. And your host for today’s program, the American Society of Hematology 2021 update, is Dr. Ghaith Abu-Zeinah from […]
Momelotinib: emerging treatment for myelofibrosis patients with anemia
Abstract The suite of marked anemia benefits that momelotinib has consistently conferred on myelofibrosis (MF) patients stem from its unique inhibitory activity on the BMP6/ACVR1/SMAD and IL-6/JAK/STAT3 pathways, resulting in decreased hepcidin (master iron regulator) expression, higher serum iron and hemoglobin levels, and restored erythropoiesis. Clinical data on momelotinib from the phase 2 and the […]
New Horizons in MPN Treatment, A Review of Therapeutic Options
Abstract Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). MPN patients have shortened survival […]
New MPN Drug Treatments in Development
by David Wallace What are some of the latest combination drug treatments in development for MPN? Find out the latest on combination add-on strategies to JAK inhibitors and other new agents. Two combination therapies for Myelofibrosis look promising as they move into phase 3 clinical trials. They include adding CPI-0610 (a bromodomain, BET, inhibitor) and […]
Protagonist Therapeutics early Phase 2 results for Polycythemia Vera Treatment Encouraging
Protagonist Therapeutics Announces Initial Phase 2 Results with Hepcidin Mimetic PTG-300 in the Treatment of Polycythemia Vera PTG-300 treatment demonstrates robust clinical response and provides clinically meaningful dose related control of hematocrit values on individual patient basis Results to be presented today by Ronald Hoffman, M.D., Director of the Myeloproliferative Diseases Program at The Icahn […]
